Vuzix Receives $1 Million for R+D of Holographic Optical Display System

The Persistent Close Air Support (PCAS) program from Defense Advanced Research Projects Agency's (DARPA) has awarded Vuzix Corporation with a research contract worth $1 million.

The funding is directed towards R&D of advanced holographic optical display solution based on Blade Optical system, a patented technology from Vuzix. The next generation see-through holographic optic and a high definition micro display developed by Vuzix will be applied in Joint Terminal Attack Controllers (JTAC). Vuzix has started production deliveries of comparable but present generation equipment for the Battlefield Air Operations Kit.

The $1 million award will fund a development program for prototype systems, which will be combined into a larger PCAS program. PCAS will raise the CAS capabilities for both airborne and JTAC platforms by developing technologies that will supply the supported ground commander with continuous lethality and CAS availability. The system will be designed to decrease potential fratricide and collateral damage and thereby improve the effectiveness and safety of the ground forces.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Choi, Andy. (2019, February 28). Vuzix Receives $1 Million for R+D of Holographic Optical Display System. AZoOptics. Retrieved on November 21, 2024 from https://www.azooptics.com/News.aspx?newsID=13602.

  • MLA

    Choi, Andy. "Vuzix Receives $1 Million for R+D of Holographic Optical Display System". AZoOptics. 21 November 2024. <https://www.azooptics.com/News.aspx?newsID=13602>.

  • Chicago

    Choi, Andy. "Vuzix Receives $1 Million for R+D of Holographic Optical Display System". AZoOptics. https://www.azooptics.com/News.aspx?newsID=13602. (accessed November 21, 2024).

  • Harvard

    Choi, Andy. 2019. Vuzix Receives $1 Million for R+D of Holographic Optical Display System. AZoOptics, viewed 21 November 2024, https://www.azooptics.com/News.aspx?newsID=13602.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.